Alivexis has signed an exclusive license agreement with Melodia Therapeutics to develop, manufacture & commercialize its MDI-0151. Both will use their drug discovery knowledge to generate PoC
The agreement provides Melodia with exclusive global rights to develop, manufacture & commercialize MDI-0151. Alivexis will receive an aggregate of ~$275M upfront as well as development & sales milestones, plus royalties along with warrants for Melodia’s common shares
Melodia will begin MDI-0151’s IND-enabling process to conduct a P-I/IIa trial for treating refractory inflammatory diseases caused due to excessive neutrophil activation incl. ANCA-associated vasculitis & other related diseases
Ref: Alivexis | Image: Alivexis
Related News:- OSE Immunotherapeutics Highlights Preclinical Data of mRNA Therapeutic Platform to Treat Inflammatory and Autoimmune Disorders at FOCIS 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
